Xellia

Xellia ApS
Company typeAktieselskab
IndustryPharmaceuticals, health care[1]
Founded1958[1]
HeadquartersCopenhagen, Denmark[1]
Websitehttp://www.xellia.com

Xellia Pharmaceuticals is the global leader in fermentation-based non-beta-lactam anti-infectives. We manufacture and supply Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Forms (FDFs) to over 500 pharmaceutical companies across 80 countries.

The European Union and the World Health Organization recognize a variety of our products as essential and critical medicines, serving as crucial resources in the fight against severe infections and antimicrobial resistance.

Headquartered in Denmark, Xellia Pharmaceuticals boasts a global footprint, with manufacturing sites in Copenhagen, Denmark; Budapest, Hungary; and Taizhou, China, alongside R&D and commercial operations in an additional seven locations around the world. We stand as the sole European manufacturer of several of our products and possess a rich legacy of over 120 years in the pharmaceutical industry.

Further information about Xellia can be found at: www.xellia.com

Connect with us on LinkedIn

Products

The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.

Active drug substances manufactured are:[2]

ATC Substance Structural formula Formulation for sale Production started
D06AX05 (WHO) (FK)
J01XX10 (WHO) (FK)
R02AB04 (WHO) (FK)
QA07AA93 (WHO) (FK) 		Bacitracin (MT)[3][4] Bacitracin 1952
D06AX05 (WHO) (FK)
J01XX10 (WHO) (FK)
R02AB04 (WHO) (FK)
QA07AA93 (WHO) (FK) 		Bacitracin (MT)[3][4] Bacitracin zinc 1958
Colistimethate natrium (CMS)
A07AA10 (WHO) (FK)
J01XB01 (WHO) (FK)
QJ51XB01 (WHO) (FK) 		Colistin Colistin sulfate 1969
J01X X09 Daptomycin (MT)[3][5] Daptomycin
R02AB30 (WHO) (FK) Gramicidin
A07AA05 (WHO) (FK)
J01XB02 (WHO) (FK)
S01AA18 (WHO) (FK)
S02AA11 (WHO) (FK)
S03AA03 (WHO) (FK)
QJ51XB02 (WHO) (FK) 		Polymyxin B (MT)[3][6] Polymyxin B-sulfate 1968
J01GB01 (WHO) (FK)
S01AA12 (WHO) (FK) 		Tobramycin (MT)[3][7] Tobramycin sulfate 2005
D06AX08 (WHO) (FK)
R02AB02 (WHO) (FK)
S01AA05 (WHO) (FK) 		Tyrothricin Tyrothricin
A07AA09 (WHO) (FK)
J01XA01 (WHO) (FK) 		Vancomycin (MT)[3][8] Vancomycin hydrochloride 2003
A01AB04 (WHO) (FK)
A07AA07 (WHO) (FK)
G01AA03 (WHO) (FK)
J02AA01 (WHO) (FK) 		Amfotericin B (MT)[3][9] Amfotericin B 1985
J02AX04 (WHO) (FK) Caspofungin (MT)[3][10] Caspofungin acetate
D07AC17 (WHO) (FK)
R01AD08 (WHO) (FK)
R01AD58 (WHO) (FK)
R03BA05 (WHO) (FK) 		Fluticasone (MT)[3][11] Fluticasone propionate
D07AC13 (WHO) (FK)
R01AD09 (WHO) (FK)
R03BA07 (WHO) (FK) 		Mometasone (MT)[3][12] Mometasone furoate

Discontinued products

Previously the company also produced:

Ingredient Produced
Neomycin 1952-?
Tetracycline 1961-?

Partnerships

In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market.[13][14][15][16][17]

China-US Trade War

Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war.[18]

See also

References

  1. ^ a b c "Xellia Pharmaceuticals ApS". Bloomberg. 2019-05-15. Retrieved 15 July 2019.
  2. ^ produktet listen er hentet fra Api på xellia.com Archived 2015-08-27 at the Wayback Machine 15. august 2014 og supplert med informasjon fra Vår arv Archived 2015-08-24 at the Wayback Machine hentes samme dag
  3. ^ a b c d e f g h i j "Godkjent eller ikke godkjent – hvilke statuser kan et legemiddel ha?". Archived from the original on 28 August 2016. Retrieved 27 August 2016.
  4. ^ a b "Legemiddelsøk". Retrieved 27 August 2016.
  5. ^ "Legemiddelsøk". Retrieved 27 August 2016.
  6. ^ "Legemiddelsøk". Retrieved 27 August 2016.
  7. ^ "Legemiddelsøk". Retrieved 27 August 2016.
  8. ^ "Legemiddelsøk". Retrieved 27 August 2016.
  9. ^ "Legemiddelsøk". Retrieved 27 August 2016.
  10. ^ "Legemiddelsøk". Retrieved 27 August 2016.
  11. ^ "Legemiddelsøk". Retrieved 27 August 2016.
  12. ^ "Legemiddelsøk". Retrieved 4 September 2016.
  13. ^ "Xellia to produce Civica antibiotics". Chicago Daily Herald. 2019-05-15. Retrieved 15 July 2019.
  14. ^ "Two crucial antibiotics are the first products of Utah's new nonprofit drug company". Salt Lake Tribune. Retrieved 15 July 2019.
  15. ^ "Drugmaker Created To Reduce Shortages And Prices Unveils Its First Products". NPR. Retrieved 15 July 2019.
  16. ^ Evans, Melanie (15 May 2019). "Hospital Drug-Making Venture Picks Antibiotics as First Products". Wall Street Journal. Retrieved 15 July 2019.
  17. ^ Deam, Jenny (20 May 2019). "Unique initiative to lower drug prices signs manufacturer". Houston Chronicle. Retrieved 22 July 2019.
  18. ^ "Trade War With China Threatens To Make Problems With Generic Medicine Worse". Forbes. Retrieved 15 July 2019.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.